A blend usually described as GHK-Cu, BPC-157, TB-500, and KPV. People discuss it for recovery, skin, and inflammation.
5-minute readFull profile reviewed July 25, 2026
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
KLOW blend at a glance
Why people look into it, what studies found, and what is still unknown.
Why people look into it
Whether adding these ingredients together changes healing or inflammation-related outcomes.
What studies found
No controlled or registered study of the complete blend was located. Evidence for the ingredients varies and cannot establish a combined effect.
What is still unclear
The exact formula can vary. Benefits, interactions, stability, and safety of the complete blend remain unknown.
About the evidence and review date
Educational information only. Evidence reviewed through July 25, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Why people research it
Each label shows how much evidence supports that question.
Skin appearance and repairIngredient studies only
Wound and injury recoveryIngredient studies only
Gut-inflammation researchIngredient studies only
Benefit from the combined blendNot demonstrated
What studies show
What the evidence supports
The research behind the answer
None for KLOW as a blend. The strongest component-level human evidence
comes from specific topical GHK-Cu studies; it cannot establish
injectable KLOW.
See each finding and its sources (8)
No direct evidence located
KLOW is an informal blend label, not a standardized active pharmaceutical ingredient.
Peptide Relay uses KLOW to organize discussion of mixtures labeled as GHK-Cu, BPC-157, TB-500, and KPV. The name does not define a regulator-recognized identity, fixed ratio, formulation, or quality standard.
A label alone cannot verify what a particular product contains. Composition and ratios may vary.
Relay identity definition: This statement defines how Relay organizes a nonstandard market label. It is not an empirical outcome claim or verification of any product's contents.
No direct evidence located
No peer-reviewed or registered study of the exact GHK-Cu, BPC-157, TB-500, and KPV combination was located.
Searches of PubMed and ClinicalTrials.gov through July 25, 2026 did not identify a study administering all four together.
A no-results search is time-limited and cannot prove that no unpublished use has occurred.
Adding KPV to the components associated with GLOW does not create evidence for synergy or a broader healing effect.
KPV findings come from cell systems, mouse inflammatory models, engineered delivery systems, and excised skin. They do not show that KPV improves the other ingredients or the mixture.
A different proposed pathway is not evidence of complementary clinical action.
KLOW has no direct human evidence, and two of its named components have no identified human exposure.
FDA found no TB-500 or KPV administration to humans by any route. The remaining component records are also formulation- and route-specific and do not establish the blend.
Human evidence for one component cannot establish exposure, benefit, or safety for another component or the mixture.
The small BPC-157 plus thymosin-beta-4 knee report is not evidence for KLOW.
Only four people received the two-material treatment, no one received GHK-Cu or KPV, there was no comparison group, and the report does not verify TB-500 identity.
An uncontrolled four-person subgroup cannot isolate a combination effect or be expanded to a four-component blend.
Peer reviewedMethods, intervention groups, and outcomes
No evidence establishes KLOW compatibility, stability, receptor complementarity, absence of interaction, or a synergy score.
Separate mechanisms do not show that four peptides remain chemically stable together, avoid aggregation, retain potency, or produce a favorable biological interaction.
No known duplicate receptor or reported interaction is not evidence of compatibility or safety.
Regulatory sourceIngredient-level aggregation, impurity, immunogenicity, and limited-human-data concerns
KLOW is not FDA approved, and ingredient-level compounding actions do not approve the blend.
The four named components have distinct regulatory histories. Advisory votes or category placement for an ingredient do not establish approval, safety, effectiveness, or compounding eligibility of the mixture.
Regulatory status can change and should be checked ingredient by ingredient.
Relay has not verified a clear pattern of side effects for this compound.
Evidence boundary
Human exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
Missing reports do not establish safety. Findings apply to the product, route, amounts, population, comparison, and follow-up studied.
Side-effect frequency, study withdrawals, and gaps
How often side effects occurred
The available information does not reliably show how often particular side effects occur.
Evidence boundary
Under-detected or under-reported events must not be described as rare.
Why people stopped in studies
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundary
This is an evidence gap, not proof that discontinuations did not occur.
Warning information
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundary
No FDA-approved GHK-Cu/BPC-157/TB-500/KPV fixed-combination product
was located. Ingredient-level compounding reviews and advisory actions
do not approve the blend.
The blend's identity and ratio, chemical and physical compatibility,
stability after mixing, sterility, pharmacokinetics, interactions,
immunogenicity, dose-response, safety, and clinical effects.
Emergency instructions
This profile does not contain verified, product-specific emergency instructions.
Evidence boundary
Relay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Dosing & preparation
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Route: Route unverified · No exact human administration route established in this review
Evidence gap · Route unverified
No verified regimen for this exact identity
KLOW formulations and ratios can vary. Adding KPV to other components does not create a studied combined dosing schedule.
What would fill this gap: A formulation-matched human combination protocol.
Dosing review checked Oct 20, 2026. Additional sources are available below.
Formulation & handling · Route unverified
No route-specific preparation instructions were verified. A different route or product does not supply them.
Starting dose, maintenance, and trial targets explained
Starting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
Other source records, populations, and limits · all routes
No direct study for this identity
KLOW fixed-combination evidence
Amount in this source
A complete human regimen was not verified in this source record. See the dosing status above.
Frequency
Not established in published research
Route
No verified route for a standardized KLOW formulation
Duration
Not established in the reviewed record
Population, study design, and limitations
No verified study was located that administered the four named components together as one reproducible KLOW formulation. Ingredient-level evidence cannot establish a mixture result.
Population: No directly studied human population was verified for this identity.
Design: No direct controlled or registered blend study located
Two named components lack identified human administration evidence, and the better-studied component records use different formulations and routes.
The section remains incomplete because no blend-specific identity, compatibility, exposure, safety, or outcome record was found.
No direct primary administration source was verified for this exact identity.
Mechanisms
How it works
KLOW combines four proposed components with materially different
identities and evidence records. GHK-Cu human evidence is mainly
topical and formulation-specific. BPC-157 has predominantly preclinical
evidence, small uncontrolled human reports, and a registered Phase 2
trial without results. FDA located no human TB-500 or KPV
administration by any route. KPV's inflammatory findings come from
cell systems, animal models, engineered delivery formulations, and
excised skin. No pharmacokinetic, compatibility, stability, interaction,
safety, or efficacy study of the exact four-component mixture was
located.
Why this matters
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Signals and targets
No validated direct KLOW targetNo validated molecular target for BPC-157No validated cell-surface receptor for GHK-CuNo established human pharmacologic target for TB-500No validated pharmacologic receptor target for KPV
Proposed biological steps
GHK-Cu: copper binding and extracellular-matrix signaling
BPC-157: proposed vascular, fibroblast, nitric-oxide, and inflammatory signaling
TB-500: proposed actin-region biology based on a seven-amino-acid fragment
KPV: preclinical PepT1 transport and inflammatory-signaling effects
No demonstrated blend mechanism or synergy
Research reference
How mature is the evidence?
A reference for the studies, populations, and routes behind this profile.
Research depthNo direct blend program
The available record consists of four separate ingredient records and documented searches that found no exact-combination study.
Why this matters
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Evidence confidenceVery low for blend outcomes
No direct evidence establishes benefit, synergy, compatibility, stability, safety, or pharmacokinetics for the four-component mixture.
Why this matters
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
Strongest evidenceSeparate-component studies only; none administered the defined KLOW blendWhy this matters
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human evidenceNo verified direct human KLOW study locatedWhy this matters
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
Which product or study does this describe?
KLOW fixed-combination evidence: amounts and schedules describe this route record only.
Route studiedNo verified route for a standardized KLOW formulation
Schedules studiedNot established in published research
Amounts studiedWithheld: this record provides research context without a transferable amountWhy this matters
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-lifeNot established for this exact editorial recordWhy this matters
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Route evidenceNo verified study was located that administered the four named components together as one reproducible KLOW formulation. Ingredient-level evidence cannot establish a mixture result.Why this matters
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Two named components lack identified human administration evidence, and the better-studied component records use different formulations and routes. The section remains incomplete because no blend-specific identity, compatibility, exposure, safety, or outcome record was found. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study-by-study record
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
Why this matters
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Controlled human studyPeer reviewed
Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper
PhaseSmall retrospective report — not a KLOW study
Population16 participants
DurationFollow-up timing was not standardized
Design and population
Uncontrolled retrospective report of intra-articular treatment for knee pain
16 people with several types of knee pain
Outcomes measured
Self-reported knee-pain relief
What was reported
Fourteen of 16 people reported relief overall. Three of the four people in the two-material subgroup reported relief.
Study administration and important limits
Study administration: Twelve received BPC-157 alone; four also received material described as thymosin beta-4. No GHK-Cu or KPV was used.
Limitations: There was no control group, GHK-Cu, or KPV. The four-person two-material subgroup cannot establish a combination effect, and the thymosin-beta-4 identity was not verified as TB-500.
DurationCell experiments and short experimental-colitis protocols
Design and population
Transport experiments in intestinal and immune-cell lines plus chemically induced mouse colitis models
Caco2-BBE and HT29-Cl.19A intestinal cells, Jurkat T cells, and mice with experimental colitis
Outcomes measured
PepT1-mediated uptake
NF-kB and MAPK signaling
Inflammatory cytokine expression
Mouse colitis severity
What was reported
The study reported PepT1-mediated cellular uptake, reduced inflammatory signaling in cell models, and reduced inflammation in mouse colitis models.
Study administration and important limits
Study administration: KPV exposure in cell systems and oral KPV in mouse colitis models
Limitations: Cell-line transport and mouse-colitis findings do not establish human KPV exposure, wound healing, injection effects, or any result for KLOW.